Advances in Laboratory-Based Cancer Screening and Early Detection: A Comprehensive Review of Strategies and Challenges

Article Sidebar

PDF
Published: Dec 4, 2023
DOI: https://doi.org/10.47191/ijpbms/v3-i12-01
Keywords:
.

Main Article Content

Lina Ali Hasballaha
University of Diyala, College of medicine, Diyala, Iraq
Ghazwan Talal mahdi
The Institute of Genetic Engineering and Biotechnology for the Postgraduate Studies / University of Baghdad
Manar Ibrahim Hasan
University of Diyala, College of medicine, Diyala, Iraq

Abstract

The identification and timely detection of cancer hold essential significance in mitigating the adverse health outcomes and fatalities associated with this disease. In recent years, laboratory-based approaches have emerged as invaluable tools in augmenting the accuracy and effectiveness of cancer screening processes. This comprehensive review aims to present a comprehensive overview of laboratory-based techniques utilized in cancer screening and early detection, along with the challenges encountered during their implementation. The current review provides an in-depth analysis of various laboratory methodologies utilized in the realm of cancer screening, including blood tests, molecular assays, and histopathological examination. Special attention is given to the significance of biomarkers and molecular diagnostics as powerful tools for identifying genetic mutations and alterations associated with malignancy. Furthermore, this inquiry explores the efficacy of liquid biopsies as non-invasive screening modalities and delves into the inherent challenges encountered during the analysis of these samples. Through offering a meticulous and all-encompassing survey of laboratory-based cancer screening and early detection, the present review presents invaluable discernments into the strategies employed and challenges encountered within this crucial realm of cancer investigation. The primary objective is to contribute to the advancement of laboratory practices and the optimization of screening methodologies, thereby fostering enhanced outcomes in the early detection and management of cancer.

Article Details

How to Cite
Lina Ali Hasballaha, Ghazwan Talal mahdi, & Manar Ibrahim Hasan. (2023). Advances in Laboratory-Based Cancer Screening and Early Detection: A Comprehensive Review of Strategies and Challenges. International Journal of Pharmaceutical and Bio Medical Science, 3(12), 697–708. https://doi.org/10.47191/ijpbms/v3-i12-01
Issue
Vol. 3 No. 12 (2023): Volume 03 Issue 12 December 2023
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Hasan N, Nadaf A, Imran M, Jiba U, Sheikh A, Almalki WH, et al. Skin cancer: understanding the journey of transformation from conventional to advanced treatment approaches. Mol Cancer. 2023;22(1):168.

II. Huang C, Azizi P, Vazirzadeh M, Aghaei-Zarch SM, Aghaei-Zarch F, Ghanavi J, et al. Non-coding RNAs/DNMT3B axis in human cancers: from pathogenesis to clinical significance. J Transl Med. 2023;21(1):621.

III. Loud JT, Murphy J. Cancer Screening and Early Detection in the 21(st) Century. Semin Oncol Nurs. 2017;33(2):121-8.

IV. Curry SJ, Byers T, Hewitt M. Potential of screening to reduce the burden of cancer. Fulfilling the Potential of Cancer Prevention and Early Detection: National Academies Press (US); 2003.

V. Brandt BH. Molecular diagnostics of solid malignant tumours. Clin Lab. 2002;48(11-12):605-15.

VI. Yamin D, Uskoković V, Wakil AM, Goni MD, Shamsuddin SH, Mustafa FH, et al. Current and Future Technologies for the Detection of Antibiotic-Resistant Bacteria. Diagnostics. 2023;13(20):3246.

VII. Wang Y, Douville C, Cohen JD, Mattox A, Curtis S, Silliman N, et al. Detection of rare mutations, copy number alterations, and methylation in the same template DNA molecules. Proc Natl Acad Sci U S A. 2023;120(15):e2220704120.

VIII. Sarhadi VK, Armengol G. Molecular Biomarkers in Cancer. Biomolecules. 2022;12(8).

IX. Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery and validation. Transl Cancer Res. 2015;4(3):256-69.

X. Lokshin A, Bast RC, Rodland K. Circulating Cancer Biomarkers. Cancers (Basel). 2021;13(4).

XI. David MK, Leslie SW. Prostate specific antigen. StatPearls [Internet]: StatPearls Publishing; 2022.

XII. Atan A, Güzel Ö. How should prostate specific antigen be interpreted? Turk J Urol. 2013;39(3):188-93.

XIII. Mehrmohammadi M, Yoon SJ, Yeager D, Emelianov SY. Photoacoustic Imaging for Cancer Detection and Staging. Curr Mol Imaging. 2013;2(1):89-105.

XIV. García-Figueiras R, Baleato-González S, Padhani AR, Luna-Alcalá A, Vallejo-Casas JA, Sala E, et al. How clinical imaging can assess cancer biology. Insights Imaging. 2019;10(1):28.

XV. Panunzio A, Sartori P. Lung Cancer and Radiological Imaging. Curr Radiopharm. 2020;13(3):238-42.

XVI. Patel PR, De Jesus O. CT Scan. StatPearls [Internet]: StatPearls Publishing; 2023.

XVII. Schmidt MA, Payne GS. Radiotherapy planning using MRI. Phys Med Biol. 2015;60(22):R323-61.

XVIII. Brattain LJ, Telfer BA, Dhyani M, Grajo JR, Samir AE. Machine learning for medical ultrasound: status, methods, and future opportunities. Abdom Radiol (NY). 2018;43(4):786-99.

XIX. Visioni A, Kim J. Positron emission tomography for benign and malignant disease. Surg Clin North Am. 2011;91(1):249-66.

XX. Champaign JL, Cederbom GJ. Advances in breast cancer detection with screening mammography. Ochsner J. 2000;2(1):33-5.

XXI. Heywang-Köbrunner SH, Hacker A, Sedlacek S. Advantages and disadvantages of mammography screening. Breast care. 2011;6(3):199-207.

XXII. Sachan PL, Singh M, Patel ML, Sachan R. A Study on Cervical Cancer Screening Using Pap Smear Test and Clinical Correlation. Asia Pac J Oncol Nurs. 2018;5(3):337-41.

XXIII. Hashimoto K, Nishimura S, Ito T, Oka N, Akagi M. Limitations and usefulness of biopsy techniques for the diagnosis of metastatic bone and soft tissue tumors. Ann Med Surg (Lond). 2021;68:102581.

XXIV. Yang G, Wei L, Thong BKS, Fu Y, Cheong IH, Kozlakidis Z, et al. A Systematic Review of Oral Biopsies, Sample Types, and Detection Techniques Applied in Relation to Oral Cancer Detection. BioTech (Basel). 2022;11(1).

XXV. Łukasiewicz E, Ziemiecka A, Jakubowski W, Vojinovic J, Bogucevska M, Dobruch-Sobczak K. Fine-needle versus core-needle biopsy - which one to choose in preoperative assessment of focal lesions in the breasts? Literature review. J Ultrason. 2017;17(71):267-74.

XXVI. Ponnarasu S, Schmieder GJ. Excisional Biopsy. StatPearls [Internet]: StatPearls Publishing; 2022.

XXVII. GURURAJ DH. Dr. MADHU S PATIL, MBBS. 2023.

XXVIII. Stauffer CM, Pfeifer C. Colonoscopy. 2020.

XXIX. Becker HD. Bronchoscopy: the past, the present, and the future. Clinics in chest medicine. 2010;31(1):1-18.

XXX. Cancer NCCf. Diagnosing and staging bladder cancer. Bladder Cancer: Diagnosis and Management: National Institute for Health and Care Excellence (NICE); 2015.

XXXI. Reddy Y, Willert RP. Endoscopic ultrasound: what is it and when should it be used? Clin Med (Lond). 2009;9(6):539-43.

XXXII. Meseeha M, Attia M. Endoscopic Retrograde Cholangiopancreatography. 2018.

XXXIII. Sokolenko AP, Imyanitov EN. Molecular Diagnostics in Clinical Oncology. Front Mol Biosci. 2018;5:76.

XXXIV. Thenrajan T, Alwarappan S, Wilson J. Molecular Diagnosis and Cancer Prognosis-A Concise Review. Diagnostics (Basel). 2023;13(4).

XXXV. Matias-Guiu X, Stanta G, Carneiro F, Ryska A, Hoefler G, Moch H. The leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathology. Virchows Arch. 2020;476(4):491-7.

XXXVI. Connolly JL, Schnitt SJ, Wang HH, Longtine JA, Dvorak A, Dvorak HF. Role of the Surgical Pathologist in the Diagnosis and Management of the Cancer Patient. Holland-Frei Cancer Medicine 6th edition: BC Decker; 2003.

XXXVII. Sahm F, Brandner S, Bertero L, Capper D, French PJ, Figarella-Branger D, et al. Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline. Neuro Oncol. 2023;25(10):1731-49.

XXXVIII. Luthra R, Chen H, Roy-Chowdhuri S, Singh RR. Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges. Cancers (Basel). 2015;7(4):2023-36.

XXXIX. Lippi G, Rin GD. Advantages and limitations of total laboratory automation: a personal overview. Clinical Chemistry and Laboratory Medicine (CCLM). 2019;57(6):802-11.

XL. Shiferaw MB, Yismaw G. Magnitude of delayed turnaround time of laboratory results in Amhara Public Health Institute, Bahir Dar, Ethiopia. BMC Health Services Research. 2019;19(1):240.

XLI. El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin. 2019;69(4):305-43.

XLII. Laessig RH, Ehrmeyer SS, Hassemer DJ. Quality control and quality assurance. Clin Lab Med. 1986;6(2):317-27.

XLIII. Sweeney SM, Hamadeh HK, Abrams N, Adam SJ, Brenner S, Connors DE, et al. Challenges to Using Big Data in Cancer. Cancer Res. 2023;83(8):1175-82.

XLIV. Alberto NRI, Alberto IRI, Puyat CVM, Antonio MAR, Ho FDV, Dee EC, et al. Disparities in access to cancer diagnostics in ASEAN member countries. Lancet Reg Health West Pac. 2023;32:100667.